Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects

Ji-Young Park, Kyoung Ah Kim, Pil Whan Park, Ock Je Lee, Dong Kyun Kang, Ji Hong Shon, Kwang Hyun Liu, Jae Gook Shin

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objective: Our objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Methods: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n = 5), CYP3A5*1/*3 (n = 7), or CYP3A5*3/*3 (n = 7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. Results: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5 ± 160.4 ng · h/mL [mean ± SD]) than in those with CYP3A5*1/*1 (599.9 ± 141.0 ng · h/mL) (P = .030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5 ± 0.8 L/h) and CYP3A5*3/*3 group (2.5 ± 0.5 L/h) (P = .036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2 ± 84.6) than in those with CYP3A5*1/*1 (107.5 ± 44), the difference did not reach statistical significance (P = .148). Conclusions: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.

Original languageEnglish
Pages (from-to)590-599
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume79
Issue number6
DOIs
Publication statusPublished - 2006 Jun 1

Fingerprint

Alprazolam
Cytochrome P-450 CYP3A
Healthy Volunteers
Pharmacokinetics
Genotype
Genetic Polymorphisms
Area Under Curve

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. / Park, Ji-Young; Kim, Kyoung Ah; Park, Pil Whan; Lee, Ock Je; Kang, Dong Kyun; Shon, Ji Hong; Liu, Kwang Hyun; Shin, Jae Gook.

In: Clinical Pharmacology and Therapeutics, Vol. 79, No. 6, 01.06.2006, p. 590-599.

Research output: Contribution to journalArticle

Park, Ji-Young ; Kim, Kyoung Ah ; Park, Pil Whan ; Lee, Ock Je ; Kang, Dong Kyun ; Shon, Ji Hong ; Liu, Kwang Hyun ; Shin, Jae Gook. / Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. In: Clinical Pharmacology and Therapeutics. 2006 ; Vol. 79, No. 6. pp. 590-599.
@article{b3e7eca720ba4d4b8897c810f445145c,
title = "Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects",
abstract = "Objective: Our objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Methods: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n = 5), CYP3A5*1/*3 (n = 7), or CYP3A5*3/*3 (n = 7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. Results: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5 ± 160.4 ng · h/mL [mean ± SD]) than in those with CYP3A5*1/*1 (599.9 ± 141.0 ng · h/mL) (P = .030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5 ± 0.8 L/h) and CYP3A5*3/*3 group (2.5 ± 0.5 L/h) (P = .036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2 ± 84.6) than in those with CYP3A5*1/*1 (107.5 ± 44), the difference did not reach statistical significance (P = .148). Conclusions: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.",
author = "Ji-Young Park and Kim, {Kyoung Ah} and Park, {Pil Whan} and Lee, {Ock Je} and Kang, {Dong Kyun} and Shon, {Ji Hong} and Liu, {Kwang Hyun} and Shin, {Jae Gook}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.clpt.2006.02.008",
language = "English",
volume = "79",
pages = "590--599",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects

AU - Park, Ji-Young

AU - Kim, Kyoung Ah

AU - Park, Pil Whan

AU - Lee, Ock Je

AU - Kang, Dong Kyun

AU - Shon, Ji Hong

AU - Liu, Kwang Hyun

AU - Shin, Jae Gook

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Objective: Our objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Methods: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n = 5), CYP3A5*1/*3 (n = 7), or CYP3A5*3/*3 (n = 7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. Results: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5 ± 160.4 ng · h/mL [mean ± SD]) than in those with CYP3A5*1/*1 (599.9 ± 141.0 ng · h/mL) (P = .030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5 ± 0.8 L/h) and CYP3A5*3/*3 group (2.5 ± 0.5 L/h) (P = .036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2 ± 84.6) than in those with CYP3A5*1/*1 (107.5 ± 44), the difference did not reach statistical significance (P = .148). Conclusions: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.

AB - Objective: Our objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Methods: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n = 5), CYP3A5*1/*3 (n = 7), or CYP3A5*3/*3 (n = 7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. Results: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5 ± 160.4 ng · h/mL [mean ± SD]) than in those with CYP3A5*1/*1 (599.9 ± 141.0 ng · h/mL) (P = .030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5 ± 0.8 L/h) and CYP3A5*3/*3 group (2.5 ± 0.5 L/h) (P = .036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2 ± 84.6) than in those with CYP3A5*1/*1 (107.5 ± 44), the difference did not reach statistical significance (P = .148). Conclusions: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.

UR - http://www.scopus.com/inward/record.url?scp=33744537737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744537737&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2006.02.008

DO - 10.1016/j.clpt.2006.02.008

M3 - Article

C2 - 16765147

AN - SCOPUS:33744537737

VL - 79

SP - 590

EP - 599

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -